Ropinirole
The active substance of Repirol SR is ropinirole, which belongs to a group of medicines called dopamine agonists. Dopamine agonists affect brain function in a similar way to a naturally occurring substance called dopamine.
In patients with Parkinson's disease, there is a low level of dopamine in some parts of the brain. Ropinirole works in a similar way to natural dopamine and helps to alleviate the symptoms of Parkinson's disease.
The patient should inform their doctor about these circumstances.
Before starting to take Repirol SR, the patient should discuss with their doctor or pharmacist:
The patient should consult their doctor if they, their caregiver, or their family notice that they have developed unusual behaviors (such as an uncontrollable urge or desire to engage in behaviors that may harm themselves or others). This is called impulse control disorder and may include behaviors such as compulsive gambling, overeating, or excessive spending.
The patient should contact their doctor if they or a family member notice any unusual behaviorswhile taking Repirol SR (such as an uncontrollable urge to gamble or increased libido and/or hypersexuality). The doctor may adjust the dose or stop the medicine.
The patient should tell their doctor or pharmacist about all medicines they are taking or have recently taken, including herbal medicines and other medicines available without a prescription.
The patient should inform their doctor if they are taking or have recently taken any of these medicines.
The patient should inform their doctor if they start or stop smoking while taking Repirol SR. The doctor may need to adjust the dose.
Repirol SR can be taken with or without food, as preferred by the patient.
Repirol SR should not be used during pregnancy, unless the doctor considers that the benefits to the mother outweigh the risks to the unborn child. Repirol SR should not be used during breast-feeding, as it may affect milk production.
It has not been shown that Repirol SR affects fertility in humans. If the patient is pregnant, breast-feeding, thinks they may be pregnant, or plans to have a baby, they should ask their doctor or pharmacist for advice before taking this medicine.
Repirol SR may cause drowsiness. Uncontrollable drowsiness may occur, and sometimes sudden and unanticipated episodes of sleep without prior warning of drowsiness. If these symptoms occur, the patient should not drive, operate machinery, and should notperform tasks that could put themselves or others at risk of serious injury or death. The patient should not perform these tasks until the symptoms have resolved.
During treatment with ropinirole, hallucinations (seeing, hearing, or feeling things that are not there) may occur. If the patient experiences hallucinations, they should not drive or operate machinery.
The patient should inform their doctor if they think this situation applies to them.
This medicine contains less than 1 mmol sodium (23 mg) per dose, which is essentially "sodium-free".
This medicine should always be taken exactly as prescribed by the doctor or pharmacist.If the patient is unsure, they should consult their doctor or pharmacist.
Repirol SR can be used to treat the symptoms of Parkinson's disease as a single medicine or in combination with another medicine called L-dopa (also known as levodopa). If the patient is taking L-dopa, they may experience uncontrolled movements (dyskinesias) when starting treatment with Repirol SR. If these symptoms occur, the patient should inform their doctor, who may adjust the doses of the medicines they are taking.
It may take some time to establish the correct dose of Repirol SR.
The recommended starting doseof Repirol SR is 2 mg once daily for the first week. From the second week onwards, the doctor may increase the dose to 4 mg once daily. If the patient is elderly, the doctor may prescribe a slower dose increase. The doctor will then adjust the dose until the most suitable dose for the patient is found.
Some patients may take doses up to 24 mg of Repirol SR once daily.
If the patient experiences intolerable side effects at the start of treatment, they should inform their doctor. The doctor may recommend changing the treatment to ropinirole immediate-release tablets in smaller doses taken three times a day.
Repirol SR should not be given to children.Repirol SR is not intended for use in people under 18 years old.
It may take several weeks for the beneficial effects of Repirol SR to appear.
The tablets (tablets) should not be broken, chewed, or crushed, as this may lead to overdosing, as the medicine is released too quickly into the body.
The doctor will determine the dose of Repirol SR based on the total daily dose of ropinirole previously taken in the form of immediate-release tablets. On the day before switching, the patient should take their usual dose of ropinirole immediate-release tablets. The next morning, they should take Repirol SR and not take ropinirole immediate-release tablets anymore.
The patient should immediately consult their doctor or pharmacist.If possible, they should show the packaging of Repirol SR.
Symptoms of overdosing on Repirol SR may include: nausea (vomiting), vomiting, dizziness (feeling of spinning), drowsiness, mental fatigue, or physical fatigue, fainting, hallucinations.
The patient should not takean extra dose or a double dose of the prolonged-release tablets to make up for a missed dose.
If the patient misses a dose of Repirol SR for a day or longer, they should consult their doctor for advice on restarting Repirol SR.
Repirol SR should be taken for as long as the doctor recommends.The patient should not stop taking the medicine without their doctor's advice.
If the patient suddenly stops taking Repirol SR, their Parkinson's disease symptoms may worsen rapidly. Suddenly stopping this medicine may cause a condition called neuroleptic malignant syndrome, which can be life-threatening. Symptoms include: akinesia (inability to move), muscle stiffness, fever, unstable blood pressure, tachycardia (rapid heart rate), disorientation, and impaired consciousness (e.g., coma).
If the doctor needs to stop Repirol SR, they will gradually reduce the dose.
If the patient has any further doubts about taking the medicine, they should consult their doctor or pharmacist.
Like all medicines, Repirol SR can cause side effects, although not everybody gets them. The risk of side effects is higher at the start of the first treatment and immediately after increasing the dose.
Side effects are usually mild and may become less troublesome after some time on the medicine. If the patient is concerned about side effects, they should talk to their doctor.
Very common side effects
Common side effects
Uncommon side effects
Side effects with unknown frequency
Over time, patients taking Repirol SR with L-dopa may experience other side effects, including:
If the patient experiences any side effects, including any possible side effects not listed in the leaflet, they should tell their doctor or pharmacist. Side effects can be reported directly to the Department of Drug Safety, Ministry of Health, via the website https://smz.ezdrowie.gov.pl. Side effects can also be reported to the marketing authorization holder.
The medicine should be stored out of sight and reach of children.
Do not use this medicine after the expiry date stated on the blister, bottle, and carton. The expiry date refers to the last day of the month.
Do not store above 25°C.
HDPE bottle: the shelf life after first opening is 60 days.
Medicines should not be disposed of via wastewater or household waste. The patient should ask their pharmacist how to dispose of medicines they no longer need. This will help protect the environment.
The active substance of Repirol SR is ropinirole.
Each prolonged-release tablet contains 2 mg, 4 mg, or 8 mg of ropinirole (as ropinirole hydrochloride).
The other ingredients are:
2 mg, prolonged-release tablet | hypromellose (E464); iron oxide red (E172); lactose monohydrate; titanium dioxide (E171); triacetin |
4 mg, prolonged-release tablet | macrogol 400; hypromellose (E464); orange yellow S (E110); titanium dioxide (E171); indigo carmine (E132) |
8 mg, prolonged-release tablet | hypromellose (E464); iron oxide red (E172); iron oxide black (E172); iron oxide yellow (E172); macrogol 400; titanium dioxide (E171) |
Repirol SR, 2 mg, prolonged-release tablets: pink, round, biconvex, 6.8 ± 0.1 mm in diameter and 5.5 ± 0.2 mm thick.
Repirol SR, 4 mg, prolonged-release tablets: light brown, oval, biconvex, 12.6 x 6.6 ± 0.1 mm in diameter and 5.3 ± 0.2 mm thick.
Repirol SR, 8 mg, prolonged-release tablets: red, oval, biconvex, 19.2 x 10.2 ± 0.2 mm in diameter and 5.2 ± 0.2 mm thick.
Repirol SR in all strengthsis available in PVC/PCTFE/Aluminum blisters and HDPE bottles with a PP cap and a desiccant.
Package sizes:
Blister: 21, 28, 42, 56, 84 prolonged-release tablets
Bottle: 21, 28, 42, 56, 84 prolonged-release tablets
Not all pack sizes may be marketed.
Bausch Health Ireland Limited
3013 Lake Drive
Citywest Business Campus
Dublin 24, D24PPT3
Ireland
Pharmathen S.A.
6 Dervenakion Str,
153 51, Pallini, Attiki
Greece
Pharmathen International S.A.
Industrial Park Sapes
Rodopi Prefecture
Block No 5, Rodopi 69300
Greece
Bausch Health Poland sp. z o.o.
ul. Przemysłowa 2
35-959 Rzeszów
Bausch Health Poland sp. z o. o.
ul. Kosztowska 21
Poland
Poland: Repirol SR
Date of last revision of the leaflet:June 2023
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.